Philip J Mease

Summary

Publications

  1. ncbi request reprint Development of criteria to distinguish inflammatory from noninflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA 2013 Annual Meeting
    Philip J Mease
    From Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington Department of Dermatology, Hofstra North Shore LIJ School of Medicine, Hempstead, New York, USA University of Leeds, Leeds, UK, and Bradford Hospitals National Health Service NHS Foundation Trust, Bradford, UK University of Toronto Toronto Western Research Institute Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada P J Mease, MD, Seattle Rheumatology Associates, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine A Garg, MD, Department of Dermatology, Hofstra North Shore LIJ School of Medicine P S Helliwell, DM, PhD, FRCP, Senior Lecturer in Rheumatology, University of Leeds and Bradford Hospitals NHS Foundation Trust J J Park, MD, Seattle Rheumatology Associates, and University of Washington School of Medicine D D Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Toronto Western Research Institute, South Korea
    J Rheumatol 41:1249-51. 2014
  2. pmc Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
    P J Mease
    Swedish Medical Center and University of Washington, Seattle, Washington, USA
    Ann Rheum Dis 73:48-55. 2014
  3. doi request reprint Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis
    Philip J Mease
    Swedish Medical Center and University of Washington, Seattle, WA, USA
    Drugs 74:423-41. 2014
  4. doi request reprint Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics
    Philip J Mease
    Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington Electronic address
    J Am Acad Dermatol 69:729-35. 2013
  5. ncbi request reprint GRAPPA educational initiatives: a report from the GRAPPA 2012 annual meeting
    Philip J Mease
    Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA
    J Rheumatol 40:1457-8. 2013
  6. ncbi request reprint Development of simple clinical criteria for the definition of inflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA 2012 annual meeting
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA 98122, USA
    J Rheumatol 40:1442-5. 2013
  7. ncbi request reprint Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis?
    Philip Mease
    Rheumatology Research, Swedish Medical Center Clinical Professor University of Washington School of Medicine, Seattle, USA
    Clin Exp Rheumatol 31:S59-62. 2013
  8. ncbi request reprint Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
    Philip J Mease
    Swedish Medical Center and University of Washington, Seattle, Washington, USA
    J Rheumatol 40:1407-9. 2013
  9. doi request reprint Prologue: 2011 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
    Philip J Mease
    Swedish Medical Center and University of Washington, Seattle, Washington, USA
    J Rheumatol 39:2181-3. 2012
  10. doi request reprint Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT
    Philip J Mease
    Swedish Medical Center and University of Washington, Seattle, Washington 98122, USA
    J Rheumatol 40:647-52. 2013

Detail Information

Publications84

  1. ncbi request reprint Development of criteria to distinguish inflammatory from noninflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA 2013 Annual Meeting
    Philip J Mease
    From Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington Department of Dermatology, Hofstra North Shore LIJ School of Medicine, Hempstead, New York, USA University of Leeds, Leeds, UK, and Bradford Hospitals National Health Service NHS Foundation Trust, Bradford, UK University of Toronto Toronto Western Research Institute Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada P J Mease, MD, Seattle Rheumatology Associates, Director, Rheumatology Research, Swedish Medical Center, and Clinical Professor, University of Washington School of Medicine A Garg, MD, Department of Dermatology, Hofstra North Shore LIJ School of Medicine P S Helliwell, DM, PhD, FRCP, Senior Lecturer in Rheumatology, University of Leeds and Bradford Hospitals NHS Foundation Trust J J Park, MD, Seattle Rheumatology Associates, and University of Washington School of Medicine D D Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Toronto Western Research Institute, South Korea
    J Rheumatol 41:1249-51. 2014
    ..g., dermatologists, who need assistance identifying psoriatic arthritis in patients with psoriasis, but may be useful to all clinicians in properly diagnosing rheumatologic conditions...
  2. pmc Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
    P J Mease
    Swedish Medical Center and University of Washington, Seattle, Washington, USA
    Ann Rheum Dis 73:48-55. 2014
    ..To evaluate the efficacy and safety of certolizumab pegol (CZP) after 24 weeks in RAPID-PsA (NCT01087788), an ongoing Phase 3 trial in patients with psoriatic arthritis (PsA)...
  3. doi request reprint Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis
    Philip J Mease
    Swedish Medical Center and University of Washington, Seattle, WA, USA
    Drugs 74:423-41. 2014
    ....
  4. doi request reprint Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics
    Philip J Mease
    Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington Electronic address
    J Am Acad Dermatol 69:729-35. 2013
    ..Prompt identification and treatment of psoriatic arthritis (PsA) in patients with psoriasis is critical to reducing the risk of joint damage, disability, and comorbidities...
  5. ncbi request reprint GRAPPA educational initiatives: a report from the GRAPPA 2012 annual meeting
    Philip J Mease
    Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA
    J Rheumatol 40:1457-8. 2013
    ..Finally, GRAPPA faculty presented a teaching module on PsA at an Asian regional conference in Singapore. Summaries of these activities are presented here. ..
  6. ncbi request reprint Development of simple clinical criteria for the definition of inflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA 2012 annual meeting
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA 98122, USA
    J Rheumatol 40:1442-5. 2013
    ....
  7. ncbi request reprint Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis?
    Philip Mease
    Rheumatology Research, Swedish Medical Center Clinical Professor University of Washington School of Medicine, Seattle, USA
    Clin Exp Rheumatol 31:S59-62. 2013
    ..A controlled dose-reduction and discontinuation study design is outlined, which may provide controlled evidence for such a paradigm of treatment. ..
  8. ncbi request reprint Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
    Philip J Mease
    Swedish Medical Center and University of Washington, Seattle, Washington, USA
    J Rheumatol 40:1407-9. 2013
    ....
  9. doi request reprint Prologue: 2011 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
    Philip J Mease
    Swedish Medical Center and University of Washington, Seattle, Washington, USA
    J Rheumatol 39:2181-3. 2012
    ..Introductions to these discussions are included in this prologue...
  10. doi request reprint Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT
    Philip J Mease
    Swedish Medical Center and University of Washington, Seattle, Washington 98122, USA
    J Rheumatol 40:647-52. 2013
    ....
  11. doi request reprint Psoriatic arthritis and spondyloarthritis assessment and management update
    Philip Mease
    Swedish Medical Center, Seattle WA, USA
    Curr Opin Rheumatol 25:287-96. 2013
    ....
  12. ncbi request reprint Update on treatment of psoriatic arthritis
    Philip Mease
    Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA
    Bull NYU Hosp Jt Dis 70:167-71. 2012
    ..Anti-TNF therapies remain the gold standard of effectiveness. New therapeutic options are potentially emerging including ustekinumab, abatacept, several IL-17 inhibitors, apremilast, JAK inhibitors, and possibly IL-6 inhibitors...
  13. pmc Fibromyalgia syndrome module at OMERACT 9: domain construct
    Philip Mease
    Seattle Rheumatology Associates and Division of Rheumatology Research, Swedish Medical Center, Seattle, WA 98104, USA
    J Rheumatol 36:2318-29. 2009
    ..In conclusion, a multidimensional symptom core set is proposed for evaluation of FM in clinical trials. Research on improved measures of single domains and composite measures is ongoing...
  14. ncbi request reprint Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy?
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, WA 98104, USA
    Curr Pain Headache Rep 12:399-405. 2008
    ..Trials are currently being developed to assess the potential additive or synergistic effects of combined central pharmacotherapy and to assess the safety and tolerability of this approach...
  15. doi request reprint The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial
    Philip J Mease
    Seattle Rheumatology Associates, 1101 Madison Street, Suite 1000, Seattle, WA 98104, USA
    J Rheumatol 36:398-409. 2009
    ..To evaluate the safety and efficacy of milnacipran, a dual norepinephrine and serotonin reuptake inhibitor, in the treatment of fibromyalgia (FM)...
  16. doi request reprint Estimation of minimum clinically important difference for pain in fibromyalgia
    Philip J Mease
    Swedish Medical Center and University of Washington School of Medicine, Seattle, USA
    Arthritis Care Res (Hoboken) 63:821-6. 2011
    ..To estimate the minimum clinically important difference (MCID) for several pain measures obtained from the Brief Pain Inventory (BPI) for patients with fibromyalgia...
  17. ncbi request reprint Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial
    Dafna D Gladman
    University of Toronto, and Toronto Western Hospital, Toronto, Ontario, Canada
    Arthritis Rheum 56:476-88. 2007
    ..To evaluate the efficacy and safety of treatment with adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, over 48 weeks in patients with moderate to severe psoriatic arthritis (PsA)...
  18. ncbi request reprint Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Rheumatol 33:712-21. 2006
    ..Clinical and radiographic responses were evaluated in patients with psoriatic arthritis (PsA) treated for up to 2 years with etanercept...
  19. ncbi request reprint Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis
    Philip J Mease
    Seattle Rheumatology Associates and Swedish Medical Center, 1101 Madison Street, Seattle, WA 98104, USA
    J Rheumatol 37:1221-7. 2010
    ..To evaluate the effects of etanercept treatment on patient-reported outcomes (PRO) in patients with psoriatic arthritis (PsA)...
  20. doi request reprint Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, Wahington 98104, USA
    J Rheumatol 37:692-703. 2010
    ....
  21. pmc Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update
    Philip J Mease
    Division of Rheumatology Research, Swedish Medical Center, University of Washington, Seattle, Washington, USA
    J Rheumatol 38:1487-95. 2011
    ..Final results of this work will be published in a separate report pending completion of analyses...
  22. doi request reprint Composite measures in psoriatic arthritis: GRAPPA 2008
    Dafna D Gladman
    University of Toronto, Ontario, Canada
    J Rheumatol 37:453-61. 2010
    ..e., in addition to assessment of peripheral joints, it should include assessment of sacroiliitis, spondylitis, enthesitis, and dactylitis, as well as skin and nail disease...
  23. ncbi request reprint Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA, USA
    Semin Arthritis Rheum 39:454-64. 2010
    ..To assess the long-term safety, tolerability, and efficacy of duloxetine in patients with fibromyalgia...
  24. doi request reprint Single-joint outcome measures: preliminary validation of patient-reported outcomes and physical examination
    Alison E Heald
    Targeted Genetics Corporation, Seattle, Washington, USA
    J Rheumatol 37:1042-8. 2010
    ..To assess the validity, responsiveness, and reliability of single-joint outcome measures for determining target joint (TJ) response in patients with inflammatory arthritis...
  25. doi request reprint Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008
    Christopher T Ritchlin
    Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA
    J Rheumatol 37:462-7. 2010
    ..The appearance of new therapeutic options in PsA raises the need for sensitive biomarkers for both disease activity and outcome...
  26. ncbi request reprint Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, Washington 98104, USA
    Arthritis Rheum 52:3279-89. 2005
    ..Adalimumab, a fully human, anti-tumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA)...
  27. pmc Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
    Dafna D Gladman
    University of Toronto, 399 Bathurst Street, Room 1E 410B, Toronto, Ontario M5T 2S8, Canada
    Arthritis Res Ther 12:R113. 2010
    ..To identify independent predictors of radiographic progression in psoriatic arthritis (PsA) for patients treated with adalimumab or placebo in the Adalimumab Effectiveness in PsA Trial (ADEPT)...
  28. ncbi request reprint Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA 98104, USA
    J Rheumatol 35:20-30. 2008
    ....
  29. doi request reprint Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, WA 98104, USA
    J Rheumatol 37:917-27. 2010
    ..To assess the efficacy and safety of 1 versus 2 courses of rituximab over 48 weeks in patients with rheumatoid arthritis (RA)...
  30. ncbi request reprint A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Rheumatol 35:502-14. 2008
    ..To evaluate the efficacy and safety of pregabalin for symptomatic relief of pain associated with fibromyalgia (FM) and for management of FM...
  31. doi request reprint Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction
    Philip J Mease
    Swedish Medical Center and University of Washington, Seattle, WA 98104, USA
    J Rheumatol 38:2461-5. 2011
    ..To evaluate changes in function as measured by Health Assessment Questionnaire Disability Index (HAQ-DI) and the meaningfulness of the changes, in importance and satisfaction, in patients with psoriatic arthritis (PsA)...
  32. doi request reprint Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group
    Laura C Coates
    Section of Musculoskeletal Disease, University of Leeds, Leeds, UK
    J Rheumatol 38:1496-501. 2011
    ..Further work is required within the GRACE dataset to develop an optimal composite measure for PsA. Several proposals to date have shown preliminary validity according to the OMERACT filter...
  33. doi request reprint Development of screening tools to identify psoriatic arthritis
    Patrick Dominguez
    Department of Dermatology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Curr Rheumatol Rep 12:295-9. 2010
    ....
  34. doi request reprint Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008
    Laura C Coates
    Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, UK
    J Rheumatol 37:448-52. 2010
    ..Further work is also required to examine the proposed common biomechanical basis between joint and skin, the mechanism of the resulting inflammation, and how these mechanisms differ from those seen in rheumatoid arthritis...
  35. doi request reprint Improving the routine management of rheumatoid arthritis: the value of tight control
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Rheumatol 37:1570-8. 2010
    ..A case study clearly demonstrates the benefits of the tight control approach in routine clinical practice...
  36. doi request reprint Pharmacotherapy of fibromyalgia
    Philip J Mease
    Rheumatology Research, Swedish Medical Center, Seattle, WA, USA
    Best Pract Res Clin Rheumatol 25:285-97. 2011
    ..Current therapies neither completely treat FM symptoms nor benefit all patients; thus, further research on new therapies with different mechanisms and side-effect profiles is needed...
  37. doi request reprint Psoriatic arthritis assessment and treatment update
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington, USA
    Curr Opin Rheumatol 21:348-55. 2009
    ..To review the current state of knowledge about assessment and management of psoriatic arthritis (PsA)...
  38. doi request reprint The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)
    Philip S Helliwell
    Academic Unit of Musculoskeletal Medicine, University of Leeds, Leeds, UK
    Ann Rheum Dis 72:986-91. 2013
    ..To develop new composite disease activity indices for psoriatic arthritis (PsA)...
  39. ncbi request reprint Outcome measures in psoriatic arthritis
    Dafna D Gladman
    University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto, Canada
    J Rheumatol 32:2262-9. 2005
    ..A set of domains to be included in the assessment of patients with PsA was derived, and a research agenda was developed...
  40. ncbi request reprint Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11
    Laura C Coates
    From the Division of Rheumatic and Musculoskeletal Disease, University of Leeds, UK Department of Rheumatology, St Vincent s University Hospital and Conway Institute, University College Dublin, Dublin, Ireland Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA Division of Rheumatology, Department of Medicine, University of Toronto, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada Division of Immunology Rheumatology, Stanford University, Palo Alto, California Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, and General Medicine Therapeutic Delivery Unit, Quintiles, Morrisville, North Carolina Department of Dermatology, University of Utah, Salt Lake City, Utah, USA Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, UK
    J Rheumatol 41:782-91. 2014
    ..Future plans include qualitative work with patients to explore their experience of disease activity and statistical modeling to explore how each of the proposed measures will perform in different disease subgroups. ..
  41. ncbi request reprint Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study
    Philip J Mease
    Seattle Rheumatology Associates, Division of Rheumatology Research, Swedish Medical Center, Seattle, Washington, USA
    J Am Acad Dermatol 60:402-11. 2009
    ..A single course of alefacept intramuscularly in combination with methotrexate (MTX) was effective in treating both psoriasis and psoriatic arthritis (PsA)...
  42. doi request reprint On defining musculoskeletal inflammation: a report from the GRAPPA 2011 annual meeting
    Amit Garg
    Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Rheumatol 39:2214-5. 2012
    ..In breakout group discussions, GRAPPA members discussed the difficulties in recognizing overlapping or mimicking features that may result in underdiagnosing or misdiagnosing PsA...
  43. ncbi request reprint Dermatology screening tools: project update from the GRAPPA 2012 annual meeting
    Dafna D Gladman
    University of Toronto, Toronto Western Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada
    J Rheumatol 40:1425-7. 2013
    ..An additional study of the prevalence of PsA in a large cohort of psoriasis patients, the PREPARE study, which investigated the use of screening questionnaires, was also presented. ..
  44. ncbi request reprint The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meeting
    Alice B Gottlieb
    From the Tufts Medical Center, Boston, Massachusetts Department of Dermatology, University of Colorado, Denver, Colorado, USA Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark Department of Dermatology, Hofstra North Shore LIJ School of Medicine, Hempstead, New York Department of Dermatology, University of Utah, Salt Lake City, Utah, USA Department of Dermatology, Geneva University Hospital, Geneva, Switzerland Harvard Medical School, Brigham and Women s Hospital, Boston, Massachusetts, USA University of Toronto, Toronto Western Research Institute Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada Seattle Rheumatology Associates, Rheumatology Research, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington Department of Dermatology, Emory University, Atlanta, Georgia, USA Division of Dermatology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada National Psoriasis Foundation, Japan
    J Rheumatol 41:1227-9. 2014
    ..As reported herein, the group's goal is to develop outcome measures in dermatology that address the needs of all involved. ..
  45. ncbi request reprint Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study
    Philip J Mease
    Swedish Medical Center, Seattle, Washington, USA
    Arthritis Rheum 54:1638-45. 2006
    ..To evaluate the efficacy and safety of alefacept in combination with methotrexate (MTX) for the treatment of psoriatic arthritis (PsA)...
  46. ncbi request reprint Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    Arthritis Rheum 50:2264-72. 2004
    ..In this study, we further evaluated the safety, efficacy, and effect on radiographic progression of etanercept in patients with PsA...
  47. doi request reprint Interpreting clinical trial results for moderate-to-severe rheumatoid arthritis: practical applications for rheumatology healthcare providers
    Nicole Furfaro
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Am Acad Nurse Pract 23:479-92. 2011
    ....
  48. ncbi request reprint Fibromyalgia syndrome
    Philip J Mease
    Swedish Medical Center, The University of Washington School of Medicine, Seattle, WA, USA
    J Rheumatol 32:2270-7. 2005
    ..A prioritized list of domains of FM to be investigated was thus developed, key issues and controversies in the field were debated, and consensus on a research agenda on outcome measure development was reached...
  49. doi request reprint The need to define musculoskeletal inflammation: a report from the GRAPPA 2010 annual meeting
    Amit Garg
    Department of Dermatology, Boston University School of Medicine, Boston, MA 02118, USA
    J Rheumatol 39:413-4. 2012
    ..Conclusions from breakout group discussions are summarized...
  50. doi request reprint Informing response criteria for psoriatic arthritis (PsA). II: Further considerations and a proposal--the PsA joint activity index
    Dafna D Gladman
    University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 37:2559-65. 2010
    ..To develop a recommended measure of response for use in psoriatic arthritis (PsA) clinical trials and observational cohort studies reflecting joint involvement...
  51. ncbi request reprint Clinical and genetic registries in psoriatic disease
    Dafna D Gladman
    University of Toronto, Toronto, Ontario, Canada
    J Rheumatol 35:1458-63. 2008
    ..Proceedings of these meetings are summarized...
  52. doi request reprint Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters
    April W Armstrong
    Department of Dermatology, University of California, Davis, 3301 C St, Ste 1400, Sacramento, CA 95816, USA
    JAMA Dermatol 149:577-82. 2013
    ....
  53. doi request reprint Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA 98104, USA pmease nwlink com
    Dermatology 220:1-7. 2010
    ..Psoriatic arthritis often affects patients with psoriasis...
  54. doi request reprint Psoriatic arthritis: pharmacotherapy update
    Philip J Mease
    Swedish Medical Center, Division of Rheumatology Research, Seattle Rheumatology Associates, University of Washington, 1101 Madison Street, Suite 1000, Seattle, WA 98104, USA
    Curr Rheumatol Rep 12:272-80. 2010
    ....
  55. ncbi request reprint Peripheral spondyloarthritis and psoriatic arthritis; overlaps and distinctions: a report from the GRAPPA 2012 annual meeting
    Philip S Helliwell
    Section of Musculoskeletal Disease, University of Leeds, Leeds, UK
    J Rheumatol 40:1446-9. 2013
    ..At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), some of this history was reviewed, along with the current thinking about the taxonomy of PsA within spondyloarthritis. ..
  56. doi request reprint Composite Measures in Psoriatic Arthritis: a report from the GRAPPA 2009 annual meeting
    Philip S Helliwell
    University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK
    J Rheumatol 38:540-5. 2011
    ..These issues were discussed at the 2009 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) in Stockholm, Sweden, and are summarized here...
  57. ncbi request reprint Psoriatic arthritis screening tools
    Abrar A Qureshi
    Department of Dermatology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Rheumatol 35:1423-5. 2008
    ..The development and validation of these screening tools was a major focus at the GRAPPA annual meeting at Boston in September 2007; we summarize that portion of the meeting...
  58. ncbi request reprint Psoriasis and psoriatic arthritis educational initiatives: an update from the 2013 GRAPPA Annual Meeting
    Kristina Callis Duffin
    From the University of Utah, Salt Lake City, Utah Department of Dermatology, Hofstra North Shore LIJ School of Medicine, Hempstead, New York Department of Dermatology, University of Colorado, Denver, Colorado, USA Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital, Leeds, UK Rheumatology Research, Swedish Medical Center University of Washington School of Medicine, Seattle, Washington, USA K Callis Duffin, MD, University of Utah A Garg, MD, Associate Professor, Department of Dermatology, Hofstra North Shore LIJ School of Medicine A W Armstrong, MD, MPH, Department of Dermatology, University of Colorado P S Helliwell, DM, PhD, Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital P J Mease, MD, Rheumatology Research, Swedish Medical Center Clinical Professor, University of Washington School of Medicine
    J Rheumatol 41:1240-3. 2014
    ....
  59. ncbi request reprint Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices
    Alice B Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Boston, MA 02111, USA
    J Dermatolog Treat 17:279-87. 2006
    ..To describe the skin and joint disease of patients with psoriatic arthritis being treated in dermatology clinics...
  60. ncbi request reprint Epidemiology of psoriatic arthritis in the population of the United States
    Joel M Gelfand
    Department of Dermatology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Am Acad Dermatol 53:573. 2005
    ..Estimates of the prevalence of psoriatic arthritis vary widely and are usually not determined by population-based studies...
  61. ncbi request reprint Outcome measures in psoriatic arthritis
    Dafna D Gladman
    The University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 34:1159-66. 2007
    ..This article summarizes these features of PsA as well as current knowledge on the instruments available for the assessment of these domains...
  62. doi request reprint Prologue: 2010 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
    Philip J Mease
    Swedish Medical Center and University of Washington, Seattle, Washington 98104, USA
    J Rheumatol 39:391-3. 2012
    ..Introductions to the discussions at the GRAPPA 2010 meeting are included in this prologue...
  63. ncbi request reprint Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA 98104, USA
    Expert Opin Biol Ther 5:1491-504. 2005
    ..In addition, structural changes were inhibited, and statistically and clinically significant improvements in measures of disability and quality of life were observed. Adalimumab was generally safe and well tolerated...
  64. doi request reprint Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, Washington, USA
    Am J Med 122:S44-55. 2009
    ..Pharmacologic agents that specifically target serotonin and norepinephrine reuptake may prove to be valuable tools in the treatment of fibromyalgia...
  65. doi request reprint Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
    Philip J Mease
    University of Washington, Seattle, WA 98104, USA
    J Rheumatol 38:522-5. 2011
    ..Other topics for discussion at the GRAPPA meeting included presentations on genetic associations with PsA and on comorbidities in patients with PsA. Current and future research projects also were outlined...
  66. ncbi request reprint Psoriatic arthritis therapy advances
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Rheumatology Research Division, and University of Washington School of Medicine Seattle, Washington 98104, USA
    Curr Opin Rheumatol 17:426-32. 2005
    ..This paper will review the data published in 2004 on the treatment of psoriatic arthritis, which arthritis affects 6 to 39% of all patients with psoriasis...
  67. ncbi request reprint Assessment tools in psoriatic arthritis
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Rheumatol 35:1426-30. 2008
    ..We present a review of those discussions...
  68. ncbi request reprint Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Am Acad Dermatol 54:685-704. 2006
    ....
  69. doi request reprint Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions
    Philip J Mease
    Seattle Rheumatology Associates, Rheumatology Clinical Research, Swedish Medical Center, University of Washington School of Medicine, Seattle, WA, USA
    Semin Arthritis Rheum 38:320-35. 2009
    ..To identify and describe measures that can be used to assess the impact of psoriatic arthritis (PsA) on patient functioning and health-related quality of life (HRQOL)...
  70. ncbi request reprint B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Rheumatol 35:1245-55. 2008
    ..In this review we explore the rationale behind B cell-targeted therapy, highlight the results of clinical trials with rituximab in RA and other autoimmune diseases, and describe other emerging therapies directed at B cells...
  71. ncbi request reprint Pharmacotherapy of fibromyalgia
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, WA 98104
    Rheum Dis Clin North Am 35:359-72. 2009
    ....
  72. ncbi request reprint Spondyloarthritis update: new insights regarding classifcation, pathophysiology, and management
    Philip J Mease
    University of Washington School of Medicine, Seattle, Washington, USA
    Bull NYU Hosp Jt Dis 66:203-9. 2008
    ..International treatment recommendations have been or are being developed based on the evidence base from clinical trials...
  73. ncbi request reprint Disease-modifying antirheumatic drug therapy for spondyloarthropathies: advances in treatment
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    Curr Opin Rheumatol 15:205-12. 2003
    ..This article reviews recent progress in disease-modifying therapy for spondyloarthropathy, including new biologic response modifiers, such as the tumor necrosis factor-alpha inhibitors etanercept and infliximab...
  74. doi request reprint Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA 98104, USA
    J Rheumatol 38:1546-51. 2011
    ..Evidence is presented for the efficacy of centrally acting analgesics for OA pain (opioids, antiepileptics, tricyclic antidepressants, and serotonin/norepinephrine receptor inhibitors)...
  75. doi request reprint Nursing considerations for infusion therapy in rheumatoid arthritis versus malignancy
    Nicole Furfaro
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Infus Nurs 31:350-60. 2008
    ..This article focuses on the specific pathophysiology of the RA disease state and patient characteristics that may affect infusion therapy, illustrated by a case study...
  76. pmc Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA 98104, USA
    Rheumatology (Oxford) 50:261-70. 2011
    ..CZP was generally well tolerated when used either as monotherapy or added to MTX; most adverse events were mild or moderate. Taken together, the results of these trials suggest that CZP is an effective new option for the treatment of RA...
  77. doi request reprint Psoriatic arthritis: update on pathophysiology, assessment and management
    Philip J Mease
    Seattle Rheumatology Associates, 1101 Madison St Ste 1000, Seattle, WA 98104, USA
    Ann Rheum Dis 70:i77-84. 2011
    ..Although there is considerable overlap with RA, there are some differences in pathophysiology and approach to assessment and management that are important to consider. This paper reviews these subjects, with an emphasis on recent data...
  78. ncbi request reprint Current treatment of psoriatic arthritis
    Philip J Mease
    Seattle Rheumatology Associates, Division of Clinical Research, Swedish Hospital Medical Center, University of Washington School of Medicine, Seattle, WA, USA
    Rheum Dis Clin North Am 29:495-511. 2003
    ....
  79. ncbi request reprint Recent advances in the management of psoriatic arthritis
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    Curr Opin Rheumatol 16:366-70. 2004
    ..Newer trials in psoriatic arthritis therapy demonstrate ongoing ability to control disease symptoms and signs and the progression of the disease significantly...
  80. doi request reprint Evaluation of duloxetine for chronic pain conditions
    Philip J Mease
    Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, USA Seattle Rheumatology Associates, 1101 Madison Street, Suite 1000, Seattle, WA 98104, USA
    Pain Manag 1:159-70. 2011
    ..Treatment-emergent adverse events are generally mild to moderate in severity, and tend to occur early and transiently. ..
  81. ncbi request reprint Biomarkers: project update from the GRAPPA 2012 annual meeting
    Oliver Fitzgerald
    Department of Rheumatology, St Vincent s University Hospital and Conway Institute for Biomolecular Research, University College, Dublin, Ireland
    J Rheumatol 40:1453-4. 2013
    ..GRAPPA is now ready to commence formal negotiations with potential funding partners and intends to initiate this project in the near future. ..
  82. ncbi request reprint Psoriatic arthritis - update on pathophysiology, assessment, and management
    Philip J Mease
    University of Washington School of Medicine, Seattle, Washington 98104, USA
    Bull NYU Hosp Jt Dis 68:191-8. 2010
    ..A number of advances in assessment and treatment have occurred in the last few years, which are highlighted in this update. This article reviews assessment and treatment of PsA, with an emphasis on recent data...
  83. doi request reprint Biomarkers of radiographic progression in psoriatic arthritis: a report from the GRAPPA 2011 annual meeting
    Oliver Fitzgerald
    Department of Rheumatology, St Vincent s University Hospital, Dublin, Ireland
    J Rheumatol 39:2189-92. 2012
    ....
  84. ncbi request reprint Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington, USA
    J Rheumatol 32:616-21. 2005
    ..To assess the effects of treatment with prasterone (dehydroepiandrosterone) on bone mineral density (BMD) in female patients with mild to moderate systemic lupus erythematosus (SLE) receiving chronic treatment with glucocorticoids...